An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

February 15, 2018

Type of Cancer

Hematological Malignancies

Sponsor

Principia Biopharma

Protocol Number

PRN1008-010:

To Learn More Call

(201)-510-0950